Autopsy report · NCT05435235

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

“Laboratory UNGAL”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 2 months before it started.
• Suspended: paused, and may or may not restart.
• 250 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 4

Sponsor

Albert Einstein Healthcare Network

Sponsor type

University, hospital or other

Conditions

Acute Kidney Injury; Percutaneous Coronary Intervention

Interventions

Dapagliflozin 10mg Tab

Participants

250 (planned, not actual)

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.